Matthew Hellmann

Matthew Hellmann is a leading thoracic oncologist who established tumor mutational burden (TMB) as a predictive biomarker for dual checkpoint blockade and led the CheckMate 227 trial demonstrating superior outcomes with nivolumab plus ipilimumab in high-TMB NSCLC. His research has comprehensively characterized the biology of immune response to checkpoint combinations, including clonal neoantigen load and T cell receptor diversity as predictors of benefit. He has contributed broadly to understanding primary and acquired resistance to immune checkpoint inhibitors. His translational work spans genomics, tumor immunology, and clinical trial design for lung and other thoracic cancers.